SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Spdr Dow Jones Industrial Average ETF Trust - Spdr Dow Jones Industrial Average ETF Trust

The DIA is trending lower alongside broader markets as geopolitical tensions in the Middle East and rising oil prices fuel investor anxiety over inflation and potential interest rate hikes. Traders are closely monitoring Treasury yields and upcoming economic data for clarity on the Federal Reserve's policy direction.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell Technologies shares surged following record quarterly results that significantly outperformed earnings and revenue estimates, alongside a substantial increase to its full-year revenue outlook fueled by explosive demand for AI-optimized servers. While some traders debate the long-term sustainability of the company's accounts payable-reliant growth model and margins, the dominant community sentiment remains extremely bullish regarding the company's AI-driven backlog and future performance.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The QQQ is trending lower as investors react to rising oil prices and surging U.S. Treasury yields, fueled by concerns over escalating military tensions in the Middle East and uncertainty regarding Federal Reserve rate policy. Community sentiment remains cautious as traders debate whether the market will face a correction or see a recovery driven by AI-related earnings strength.

Edison International is a renewable energy company, which operates through its subsidiaries. It supplies and distributes electric power, and also invests in energy services and technologies. The company was founded on July 4, 1886, and is headquartered in Rosemead, CA.

Edison International

Edison International shares are experiencing high volatility as traders react to reports that lawmakers failed to pass a wildfire liability reform bill, leaving the utility exposed to potential legal risks. While some investors view the resulting price drop as an overreaction and a buying opportunity, others remain cautious due to ongoing litigation and regulatory uncertainty surrounding recent wildfires.

MongoDB, Inc. engages in the development and provision of a general-purpose database platform. The firm's products include MongoDB Enterprise Advanced, MongoDB Atlas, and Community Server. It also offers professional services including consulting and training. The company was founded by Eliot Horowitz, Dwight A. Merriman, Kevin P. Ryan, and Geir Magnusson Jr. in 2007 and is headquartered in New York, NY.

MongoDB Inc - Ordinary Shares - Class A

MongoDB Inc

MongoDB shares are volatile after the company reported quarterly results that exceeded expectations and raised full-year guidance, with investors struggling to reconcile the positive earnings beat against the stock's recent sharp run-up and cautious outlook on AI revenue acceleration. The erratic price action led to significant debate among traders regarding whether the drop represents a buying opportunity or a correction of an overextended valuation.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The S&P 500 is trending lower as market participants react to escalating geopolitical tensions in the Middle East, rising crude oil prices, and climbing U.S. Treasury yields. Traders are expressing widespread concern over potential Federal Reserve interest rate hikes and the broader economic impact of these mounting macro headwinds.

PG&E Corp. operates as a holding company, which engages in generation, transmission, and distribution of electricity and natural gas to customers. It specializes in energy, utility, power, gas, electricity, solar, and sustainability. The company was founded on November 17, 1995 and is headquartered in Oakland, CA.

PG&E Corp.

PG&E shares experienced significant volatility following reports that California lawmakers blocked a legislative effort to provide wildfire liability protection for utilities. While some traders view the resulting selloff as an overreaction and speculate on a potential recovery or short squeeze, others have downgraded the stock due to lingering financial and wildfire liability risks.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is seeing heightened activity as traders speculate on the upcoming Cybercab event in Austin, with sentiment divided between enthusiasm for the robotaxi fleet expansion and skepticism regarding competitive pressures from companies like Uber. Discussion is also focused on the stock's recent volatility and its performance relative to broader market tech trends.

Vera Therapeutics, Inc. is a clinical stage biotechnical company, which engages in the development and commercialization of transformative treatments for immunological diseases. Its product includes the TRUTAKNA injection. The company was founded by Marshall W. Fordyce in May 2016 and is headquartered in Brisbane, CA.

Vera Therapeutics Inc - Ordinary Shares - Class A

The conversation is centered on anticipation for the Phase 3 ORIGIN 3 final eGFR analysis, with traders debating whether upcoming data will prove drug durability and kidney-function benefits. While some express concern over recent insider selling, bullish sentiment remains strong among many who view the upcoming readout as a potential catalyst for a significant valuation rerating or acquisition.

Vanguard Index Funds - Vanguard S&P 500 ETF

Vanguard S&P 500 ETF

The primary catalyst for VOO trending is heightened market anxiety over geopolitical instability in the Middle East and concerns regarding bond market volatility, which has led traders to debate whether current market valuations are sustainable. Discussion is fragmented between investors advocating for a "VOO and chill" long-term compounding approach and those speculating on an imminent correction due to concerns about the U.S. economy, debt levels, and the perceived overvaluation of AI-driven tech stocks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ocugen (OCGN) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls

OCGN posts a wider Q2 loss as R&D spending climbs, while advancing late-stage gene therapy programs and extending its cash runway into 2028.

Ocugen (OCGN) Reports Q2 Loss, Beats Revenue Estimates

Ocugen (OCGN) delivered earnings and revenue surprises of -40.00% and +6.29%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Illumina (ILMN) Tops Q2 Earnings and Revenue Estimates

Illumina (ILMN) delivered earnings and revenue surprises of +6.50% and +3.36%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Why Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report?

Ocugen (OCGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ocugen's Gene-Agnostic Eye Therapies Could Reshape Late-Stage Care

OCGN is advancing gene-agnostic eye therapies across retinal diseases, with key trial data and regulatory milestones approaching in 2026 and 2027.

Is OCGN Stock Worth the Risk Ahead of 2026-27 Eye Gene Therapy Data?

Ocugen faces cash burn and dilution risks, but upcoming eye gene therapy data and planned filings through 2027 could shape its next phase.

OCGN's Catalyst Calendar for Trial Data and Filings Through 2028

Ocugen's three ocular gene therapy programs could deliver trial data, filings, and potential BLA milestones through 2028 as key readouts approach.

Ocugen (OCGN) Upgraded to Buy: Here's Why

Ocugen (OCGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

OCGN Falls on Wider Q1 Loss Despite Strong Pipeline Progress Outlook

Ocugen swings to a wider Q1 loss as costs climb, but pipeline milestones and gene therapy data keep its long-term plans on track.

This account has been verified as an official OCGN representative.

Verified Account

Ocugen

Ocugen reported total revenue of $1.488 million for the second quarter of 2026, compared to $1.373 million in the prior year period, with a net loss per share of $0.07.

Ocugen faces material financial pressure from increasing operating expenses and a widening net loss, alongside inherent structural risks regarding the predictive nature of clinical data and potential regulatory interpretation differences.

Ocugen achieved significant clinical milestones across its gene therapy pipeline, secured a multi-year cash runway through strategic financing, and strengthened its operational readiness for upcoming regulatory filings and commercial launch.

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Ocugen Inc

OCGN Stock Tanks After Gene Therapy Trial Update — What Did Ocugen Announce?

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

OCGN Ocugen Inc

Fundamentals

Latest OCGN News